Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 65,000 shares, a decline of 32.0% from the November 15th total of 95,600 shares. Approximately 4.5% of the shares of the company are sold short. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 0.1 days.

Tharimmune Stock Down 1.8 %

NASDAQ:THAR traded down $0.04 during trading hours on Friday, reaching $2.14. 21,274 shares of the company’s stock were exchanged, compared to its average volume of 359,459. Tharimmune has a 1-year low of $1.84 and a 1-year high of $8.55. The company has a 50-day moving average of $2.28 and a 200 day moving average of $2.90.

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune as of its most recent SEC filing. 1.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

THAR has been the subject of a number of research analyst reports. Rodman & Renshaw started coverage on Tharimmune in a research report on Friday, December 6th. They issued a “buy” rating and a $17.00 target price for the company. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).